EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data

Mohamed R Murad iD, Ameer Awashra iD, Mohamed S Elgendy, Ahmed Wahdan Kasem, Abdalhakim Shubietah iD, Fadi Safi

Therapeutic Advances in Respiratory Disease · 2026

DOI: 10.1177/17534666261459209 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2026. Verfasst von Mohamed R Murad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA. Hauptthemen laut MEDLINE: Hemodynamics, Pulmonary Arterial Hypertension, Antihypertensive Agents, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulmonary arterial hypertension (PAH) remains progressive despite contemporary background therapy. Sotatercept is a novel activin signaling inhibitor that targets pulmonary vascular remodeling and may improve clinical and hemodynamic outcomes.

Objectives

To evaluate the efficacy, hemodynamic effects, and safety of sotatercept in patients with PAH.

Design

Systematic review and meta-analysis of randomized controlled trials (RCTs). Data sources and methods: Five electronic databases were searched through October 2, 2025, for eligible RCTs. Time-to-event outcomes were analyzed using pooled individual patient data with hazard ratios (HRs), while secondary outcomes were assessed using random-effects risk ratios (RRs) and mean differences (MDs), with 95% confidence intervals (CI). Trial-sequential analysis (TSA) evaluated the conclusiveness of results.

Results

In four RCTs ( n = 889), sotatercept reduced clinical worsening or death by 77% (HR 0.23, 95% CI 0.16–0.32, p < 0.001) and prolonged event-free survival by ~40 weeks. World Health Organization (WHO) functional class improved in 40.3% vs 24.3% (RR 1.71, 95% CI 1.32–2.21), and 6-minute walk distance increased by MD 30.27 m (95% CI 13.45–47.08), while pulmonary vascular resistance (PVR) declined significantly (MD −247 dyn·s·cm– 5 , 95% CI −301.7; −192.2). Serious adverse events were slightly less frequent with sotatercept (26.2% vs 31.7%, RR 0.83); however, total bleeding (37.9% vs 18.7%, RR 2.00), epistaxis (26.7% vs 5.4%, RR 4.89), and telangiectasia (19.8% vs 6.4%, RR 3.24) were more common. TSA revealed conclusiveness in clinical worsening, WHO functional class, and PVR, as well as increases in bleeding events and epistaxis.

Conclusion

Sotatercept significantly improves clinical outcomes and extends event-free survival in PAH, with an acceptable safety profile; however, caution is warranted regarding bleeding events. These results support its role as an add-on therapy in PAH management.

Trial registration

PROSPERO ID: CRD420251166414.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemodynamicsPulmonary Arterial HypertensionAntihypertensive AgentsRecombinant Fusion ProteinsHumansRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeProgression-Free Survival

Stichwörter der Autor:innen

clinical worseninghemodynamicsmeta-analysispulmonary arterial hypertensionsotaterceptsurvival

Substanzen

Antihypertensive AgentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Medical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
  • Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
  • Department of Medicine, An-Najah National University, Rafidia Street, P.O. Box 7, Nablus, West Bank P4110257, Palestine.
  • Faculty of Medicine, Tanta University, Tanta, Gharbia, Egypt.
  • Department of Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, USA.
  • Department of Pulmonary and Critical Care Medicine, University of Toledo, Toledo, OH, USA.

ORCID-Profile: Mohamed R Murad, Ameer Awashra, Abdalhakim Shubietah

Zitieren

APA

R Murad, M., Awashra, A., S Elgendy, M., Kasem, A. W., Shubietah, A., & Safi, F. (2026). Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666261459209

Vancouver

R Murad M, Awashra A, S Elgendy M, Kasem AW, Shubietah A, Safi F. Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data. Therapeutic Advances in Respiratory Disease. 2026. doi:10.1177/17534666261459209

BibTeX
@article{RMurad2026,
  author = {R Murad, Mohamed and Awashra, Ameer and S Elgendy, Mohamed and Kasem, Ahmed Wahdan and Shubietah, Abdalhakim and Safi, Fadi},
  title = {Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  doi = {10.1177/17534666261459209}
}
Kostenlos starten →